In September 2025, India faced a tragic public health scandal when at least 20 children died after taking a contaminated cough syrup called Coldrif. Tests revealed the medicine contained diethylene glycol (DEG)—a poisonous industrial solvent—at levels nearly 500 times above the legal limit.
Two other products, Respifresh-TR and Re-Life, were later recalled for the same reason. All three were made by licensed Indian pharmaceutical firms, not unregistered manufacturers. Yet inspections uncovered alarming lapses: filthy production environments, unqualified staff, missing quality checks, and no testing of raw ingredients like glycerine—the usual source of DEG contamination.
Were These Products Exported to the Nordics?
No. According to both India’s Central Drugs Standard Control Organisation (CDSCO) and the U.S. FDA, none of the contaminated syrups were shipped outside India. Europe, including the Nordic region, was not affected.
The World Health Organization has warned that informal or black-market channels can occasionally move such products across borders, but so far, there’s no sign this happened in Northern Europe.
Why It Still Matters for the Nordics
While the Nordics escaped direct impact, the episode underscores several broader concerns for regulators and importers:
- Import Vigilance
Nordic drug agencies must keep strict oversight of all imported medicines, particularly from countries with weaker quality control. Official trade routes are one thing; informal or counterfeit supplies are another. - Supply Chain Integrity
The crisis shows how fragile the global pharmaceutical chain can be. Both the WHO and the European Medicines Agency have called for tighter coordination on raw material sourcing and mandatory contaminant testing. - Public Awareness
Doctors, pharmacists, and parents should stay alert to the dangers of unverified over-the-counter syrups—especially those given to infants and toddlers, who are most vulnerable to DEG poisoning.
The Larger Lesson
Coldrif, Respifresh-TR, and Re-Life were commercial drugs that passed through official systems, yet still failed catastrophically. The Nordics weren’t in the distribution chain, but the case is a stark reminder: drug safety doesn’t stop at national borders.
Strong import checks, support for WHO oversight programs, and active participation in global pharmaceutical governance are essential to prevent similar tragedies—and to ensure that the next contaminated batch, wherever it’s made, doesn’t reach patients anywhere.